Followers | 86 |
Posts | 6183 |
Boards Moderated | 0 |
Alias Born | 05/27/2009 |
Thursday, January 20, 2022 9:11:14 AM
This WILL move the needle... Especially with GRAY's crazy LOW-FLOAT !
"Graybug Vision Makes Key Hires to Further Build Momentum Behind its Pipeline. January 20 2022 - 07:30AM. GlobeNewswire Inc.
Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced the hiring of six new employees who will enhance Graybug’s Research & Development (R&D), Regulatory Affairs and Program Management capabilities, as the Company further builds momentum behind its pipeline in 2022.
“We are at a critical stage in our efforts to further progress and diversify our pipeline with new, high-value programs. I strongly believe that strengthening our world-class ophthalmology team is key to our future success. I am therefore pleased to welcome several new team members, who add critical leadership in Regulatory Affairs and Program Management, as well as further deepen our teams’ capabilities in R&D,” said Fred Guerard, Pharm D, CEO of Graybug.
Among Graybug’s key hires are Fang Li, Vice President, Regulatory Affairs, and Ali Kakavand, Vice President, Head of Program Management:
- Fang Li, PhD, RAC, brings over 30 years of drug development and more than 20 years of regulatory affairs experience. She worked across small molecules, biologics, gene therapy, over-the-counter products, in-vitro diagnostic products, and medical devices, with a focus on ophthalmology. She has a proven track record in negotiating and gaining regulatory approvals in the US and other regions. Most recently, Fang was VP, Regulatory Affairs at Hurley Consulting Associated, Ltd where she led the regulatory affairs department providing strategic and operational services to clients in the pharmaceutical and biotech industry. Fang holds a doctoral degree in medicinal chemistry from China Pharmaceutical University, Nanjing, a master’s degree in organic chemistry from Wuhan University, and a bachelor's degree in organic chemistry from Xiamen University, P. R. China.
- Ali Kakavand, PhD, has over 20 years of experience in program and project management for the development of medical devices and pharmaceuticals across multiple therapeutic areas. He has extensive knowledge in the management of global clinical studies, device development, clinical manufacturing, as well as regulatory submissions. Most recently, Ali served as Director of Strategy, Program and Portfolio Management at Alexion (acquired by AstraZeneca) managing a first-of-its-kind marketed drug in hematology, as well as a drug/device combination product in phase 1 clinical development. Ali received his PhD in Biomedical Engineering from Arizona State University, where he completed his dissertation conducting research at The Neurosciences Institute in the field of Biomechanics and Neuromuscular Control.
The compensation committee of Graybug’s board of directors granted the six newly-hired employees inducement options to purchase an aggregate of 234,200 shares of Graybug common stock on January 14, 2022, as inducements material to each employee entering employment with Graybug. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $1.55 per share, which was equal to the closing price of Graybug common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of a stock option agreement covering the grant."
GLTA
.
.
....
My posts are always theory and not financial advice.
Recent GRAY News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/28/2024 11:14:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/28/2024 11:13:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/28/2024 11:11:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/28/2024 11:10:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/28/2024 11:10:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/28/2024 11:09:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/27/2024 08:42:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/27/2024 08:05:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2024 10:00:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/22/2024 10:02:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2024 08:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 08:15:08 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 07/16/2024 12:15:35 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 07/16/2024 12:05:27 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 07/16/2024 12:00:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/28/2024 10:52:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/27/2024 12:45:55 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 08:44:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 08:39:24 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 04/29/2024 12:12:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2024 01:53:21 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2024 01:49:14 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2024 01:40:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2024 01:39:37 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM